Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Brief Summary: The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks compared to treatment with sofosbuvir (SOF) plus ribavirin (RBV) for 12 weeks in participants with chronic genotype 2 hepatitis C virus (HCV) infection.


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO4588161 | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO4588161 | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO4588161 | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO4588161 | Arm Label: Group 5; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO4588161 | Arm Label: Group 6; Type: EXPERIMENTAL; Interventions: Drug: Copegus, Drug: Pegasys, Drug: RO4588161 | Arm Label: Group 7; Type: ACTIVE_COMPARATOR; Interventions: Drug: Copegus, Drug: Pegasys | Intervention Type: DRUG; Name: Copegus; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 4, Group 5, Group 6, Group 7 | Intervention Type: DRUG; Name: Pegasys; Assigned to Arm(s): Group 1, Group 2, Group 3, Group 7 | Intervention Type: DRUG; Name: Pegasys; Assigned to Arm(s): Group 4, Group 5, Group 6 | Intervention Type: DRUG; Name: RO4588161; Assigned to Arm(s): Group 1, Group 5 | Intervention Type: DRUG; Name: RO4588161; Assigned to Arm(s): Group 2, Group 3, Group 6 | Intervention Type: DRUG; Name: RO4588161; Assigned to Arm(s): Group 4
B: Arm Label: 20mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 48mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 120mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: 240mg; Type: EXPERIMENTAL; Interventions: Drug: BI201335 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 240mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 120mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 48mg | Intervention Type: DRUG; Name: BI201335; Assigned to Arm(s): 20mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Velpatasvir 5 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 100 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1b); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 4); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir up to 400 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Velpatasvir; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2)
D: Arm Label: SOF/VEL; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV

Answer: D